In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
Litt's app available free to subscribers - download for IOS and Android from the App Store or Google Play.
- TRADE NAMES: Aralen (Sanofi-Aventis); Avloclor; Chlorquin; Emquin; Heliopar; Lagaquin; Malarivon
- INDICATIONS: Malaria, rheumatoid arthritis, lupus erythematosus
- CLASS: Antimalarial, Antimicrobial, Antiprotozoal, Covid-19 putative drug, Disease-modifying antirheumatic drug (DMARD)
- HALF-LIFE: 3–5 days
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Acitretin, Antacids, Arsenic, Cholera Vaccine, Cholestyramine, Citalopram, Dapsone, Dasatinib, Degarelix, Dolasetron, Droperidol, Ethosuximide, Furazolidone, Halofantrine, Hydroxychloroquine, Lacosamide, Lanthanum, Lapatinib, Levofloxacin, Methotrexate, Methoxsalen, Mivacurium, Moxifloxacin, Neostigmine, Nilotinib, Oxcarbazepine, Pazopanib, Penicillamine, Ribociclib, Sulfonamides, Telavancin, Telithromycin, Tiagabine, Typhoid Vaccine, Vandetanib, Vigabatrin, Voriconazole, Vorinostat, Ziprasidone
- See adverse reactions attributed to class:
Investigated for treating COVID-19.
Please login to view the rest of this drug profile.
Page last updated 07/31/2023
